<DOC>
	<DOCNO>NCT02866253</DOCNO>
	<brief_summary>The purpose study compare effect pre-IVF cycle treatment without DHEA ( Dehydroepiandrosterone ) ovarian reserve marker , number oocyte obtain IVF ( vitro fertilization ) outcomes DOR ( diminish ovarian reserve ) patient expression BMP-15 ( bone morphogenetic protein 15 ) , GDF-9（growth differentiation factor 9 ) IGF-I ( insulin-like growth factors-1 ) follicular fluid .</brief_summary>
	<brief_title>Dehydroepiandrosterone ( DHEA ) Supplementation Pre-IVF ( In Vitro Fertilization ) Cycles</brief_title>
	<detailed_description>78 patient enrol accord inclusion criterion . They randomize two group , 40 DHEA group 38 control group . The DHEA group receive DHEA ( Lab Hercules™ ) 25mg three time day continue 12 week prior start IVF treatment till day egg collection control group get without DHEA treatment . All IVF woman patient give CC ( clomifene citrate ) +HMG ( human menopausal gonadotropin ) protocol control ovarian hyperstimulation . Hormonal profile include E2 ( estradiol ) , FSH ( follicle-stimulating hormone ) , P ( progesterone ) , LH ( luteinizing hormone ) , T ( testosterone ) , AFC ( antral follicle account ) , serum follicle AMH ( anti-Mullerian hormone ) level repeat follicular phase ( D2 3 ) cycle follow IVF treatment use CC+HMG protocol base standard departmental regimen . Improvement ovarian reserve marker would assess change serum follicle AMH level . Cycle characteristic include dose gonadotrophin use , duration stimulation , number oocyte obtain , number fertilize embryos good quality embryo record follicular fluid save test DHEA-S ( Dehydroepiandrosterone sulfate ) IGF-I . BMP-15 GDF-9 expression follicular fluid detect western blot .</detailed_description>
	<mesh_term>Infertility</mesh_term>
	<mesh_term>Dehydroepiandrosterone</mesh_term>
	<criteria>Patients antral follicle count &lt; 5 AMH &lt; 1.1ng/ml previous poor ovarian reserve ( POR ) ( &lt; /= 3 oocyte conventional stimulation protocol use least 150 IU FSH per day , least two episode ) Patients polycystic ovary polycystic ovary syndrome , patient previous chemotherapy , pelvic irradiation ovarian surgery patient hormonal supplementation indication time recruitment ( e.g . estrogen , testosterone DHEA ) .</criteria>
	<gender>Female</gender>
	<minimum_age>25 Years</minimum_age>
	<maximum_age>42 Years</maximum_age>
	<verification_date>August 2016</verification_date>
	<keyword>Dehydroepiandrosterone（DHEA）</keyword>
	<keyword>DOR（Diminished Ovarian Reserve )</keyword>
	<keyword>IVF ( In vitro fertilization )</keyword>
	<keyword>BMP-15 ( Bone Morphogenetic Protein 15 )</keyword>
</DOC>